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Abstract
Hemofiltration as an adjunct to therapy for sepsis is now 10 years old. Despite early
successes and significant theoretical advantages, the treatment remains experimental.
Although feasibility has been established, efficacy has proved to be much more difficult.
Clinical as well as technical difficulties remain important considerations to future studies.
These issues are discussed and the brief history of hemofiltration in sepsis is reviewed.
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A decade has past since Stein et al [1] first described an
improvement in hemodynamics associated with hemofiltra-
tion in the pig after the administration of intravenous endo-
toxin. A short time later these findings were confirmed by
Grootendorst et al [2], who also found that the ultrafiltrate
removed from endotoxemic animals produced hemody-
namic instability in healthy animals when it was infused intra-
venously [3]. Around this time, Lee et al [4] reported a
survival benefit associated with hemofiltration in septic pigs,
and Bellomo et al [5] showed that some of the interleukins
and tumor necrosis factor could be removed from the circu-
lation of humans with sepsis. With these advances, blood
purification as a treatment for human septic shock was
born. Despite its promising start, however, hemofiltration as
a treatment for sepsis has been slow to mature.
There are numerous reasons for this stunted growth. First,
several pharmacologic agents are more effective than
hemofiltration in reducing serum cytokine activity, and yet
none have been shown to produce a survival benefit.
Indeed, several spectacular failures have occurred as a
result of attempts to modulate the inflammatory response
in sepsis, occasionally even resulting in increased mortal-
ity [6]. Another reason is that 10 years ago our concepts
of sepsis were different. Sepsis was viewed as a condition
in which the local inflammatory response had become
generalized and uncontrolled. Immune effector cells, espe-
cially neutrophils, possess potent cytotoxic capacity, and
when unchecked this response can cause significant
tissue injury. More recently, however, we have come to
appreciate that although this is true, sepsis is also a syn-
drome of immune suppression. Immune effector cells
become dysfunctional and are no longer capable of
normal immune surveillance. Such a condition results in
increased susceptibility to recurrent infection, prolonged
inflammation, and continued tissue injury. Therapy aimed
at reducing the inflammatory response by removing some
of the proinflammatory stimuli may not restore immuno-
logic balance, and thus may not improve outcome. Finally,
sepsis may not be a form of intravascular inflammation as
originally thought, but rather may be a disseminated local
inflammation in which the actual process occurs at the
tissue level, and that which appears in the circulation is
only the ‘spill-over’.Critical Care    Vol 4 No 2 Kellum and Bellomo
For these reasons, the ideal immune-modulating strategy
would be one that restores immunologic stability, rather
than blindly inhibiting or stimulating one or another compo-
nent. Such a strategy would counter the immunologic
instability of sepsis, perhaps by reducing the activity of a
wide array of both proinflammatory and anti-inflammatory
molecules. Such a strategy would ‘autoregulate’ itself,
such that as one component of the response increased,
so too would the effect on that component. Finally, the
ideal strategy might well be limited in its effect to the cir-
culating pool of mediators, rather than influencing the
tissue levels where their activity may be beneficial. In
theory, hemofiltration fulfills this ideal paradigm. Indeed,
hemofiltration is perhaps the only available treatment strat-
egy that can, in theory, achieve all of these goals.
Technical considerations must also be taken into account
when assessing the current performance as well as the
potential of blood purification therapies in sepsis. Not all
hemofiltration modalities are the same. Continuous ven-
ovenous hemofiltration (CVVH) at 2 l/h of plasma water
exchange is very different from continuous venovenous
hemodialysis (CVVHD) with pure diffusive clearance when
it comes to middle molecular clearance [7,8]. Adding
500 ml/h convective clearance will also yield a very differ-
ent pattern of blood purification and very different effects.
Clinicians need to understand that these ‘technical’ differ-
ences matter a great deal. Current membranes also differ
very much from one another in their adsorptive capacity
for mediators (ie not all membranes are created equal) [9].
Importantly, even with optimal membranes and convective
clearance at 2 l/h we may be operating at inadequate
levels of blood purification to meet the goal of restoring
immune balance during severe sepsis. High-volume
hemofiltration may be necessary to achieve degrees of
blood purification that can make a predictable clinical dif-
ference [10]. Furthermore, cytokine clearance is still sub-
optimal with current membranes, and higher porosity
devices need to be tested. If one uses plasmafilters to
overcome the problem of limited porosity, one has to deal
with the extraordinary logistics of continuous plasma
exchange. Even when such problems are overcome for
48 h [11], the results are not impressive, possibly because
clearances remain relatively low (20–30 ml/min).
Presently, the cost of such plasma exchange therapy is
also prohibitive. The use of plasmafiltration with sorbent
technology may be another cost-effective and efficacious
way of approaching this problem. Such coupled filtra-
tion–adsorption appears to restore in vitro monocyte
responsiveness to endotoxin and to remove cytokines with
high efficiency [12]. Thus, quite apart from conceptual
issues of whether blood purification is a rational approach
to sepsis treatment, there are major technical matters that
need to be properly addressed if we truly wish to test the
hypothesis that blood purification has a role as adjunctive
management in sepsis.
In addition, testing this hypothesis will require the devel-
opment of better tools to accurately assess the impact of
‘broad-spectrum’ immunomodulation on the inflammatory
response. Sepsis and multiorgan failure are complex syn-
dromes and the determinants of mortality in patients suf-
fering from these syndromes are usually multifactorial.
Very large randomized trials, perhaps enrolling thou-
sands of patients, will be necessary to establish the effi-
cacy of any therapy. Before these trials are established,
however, it is necessary to understand whether hemofil-
tration has the capacity to affect the immune status of
patients in beneficial ways. The first few steps in this
process have already been achieved. Hemofiltration can
remove a wide array of inflammatory mediators from the
circulation [13,14]. To date, more than 30 studies have
shown that cytokines and other small soluble molecules
can be removed using this technique, although the size
of the effects and the mechanisms (sieving versus
adsorption) are still in question. Next, it has been estab-
lished in both humans [8] and animals [15] that hemofil-
tration can alter the circulating concentrations of some
mediators. The next logical step is to determine whether
these alterations in the plasma produce beneficial
effects on immune effector cells.
The study by Toft et al [16] in a recent issue of Critical
Care  is the first attempt to investigate the effects of
hemofiltration on the activation status of leukocytes. The
authors examined a panel of adhesion molecules, includ-
ing CD11b, on the surface of granulocytes and lympho-
cytes, in order to assess their activation status, but were
unable to find any effects of hemofiltration, save for the
uncertain finding that the percentage of CD3+ T cells
increased over time. Unfortunately, their study design is
reminiscent of many earlier studies, which also failed to
show any important immunologic effects of hemofiltration.
First, and most importantly, the study is uncontrolled. The
immune status of patients with sepsis is not static. The
activation status of leukocytes, like the circulating level of
any given inflammatory mediator, varies with time. Without
controlling for the effects of time, we cannot expect to dis-
cover what effect, if any, hemofiltration exerts on the
immune status of the patient. Secondly, Toft et al used a
less than ideal form of therapy. Although they did use
AN69 membranes, they used CVVHD (actually continuous
venovenous hemodiafiltration with very low-dose ultrafiltra-
tion). Because most of the mediators of inflammation are
not removed to a significant degree, if at all, by diffusion, it
is not surprising that this study was negative. Finally, even
if the study had been controlled, the small sample size
would make the study very difficult to interpret. Baseline
heterogeneity was large for most of the key variables and
therefore it would be difficult to compare individual
patients. Thus, although Toft et al [16] set out in the right
direction, their methods were inadequate to answer the
important questions they were attempting to address.http://ccforum.com/content/4/2/069
It is hoped that future studies will not repeat the mistakes
of the past. Hemofiltration may one day have a place in the
management of sepsis and multiorgan failure. Then again
it may not. The only way to tell will be to conduct carefully
controlled studies designed to evaluate the effects of this
therapy on immune effector cell function. If these studies
prove that hemofiltration has the potential to be useful, as
suggested by animal experiments, then large randomized
studies comparing survival will be warranted. Even before
this point is reached, however, clinicians who care for criti-
cally ill patients with sepsis and renal failure will need to
decide whether hemofiltration or hemodialysis is the most
appropriate therapy. This decision has traditionally been
made on the basis of the hemodynamic stability of the
patient. The results of the study by Toft et al [16], which
albeit was small and uncontrolled, suggest that immuno-
logic stability should also be considered. Although the
study failed to show any change in immunologic status
with CVVHD, other studies [17,18] have shown adverse
immune consequences of intermittent hemodialysis.
Studies that compare intermittent with continuous thera-
pies are urgently needed, in hemodynamically stable
patients, in order to understand what effects these thera-
pies may have on immune function.
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